4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2019 by 4BIO Ventures Management Ltd

Takeda announces its intention to acquire TiGenix

January 5, 2018

TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today confirms that Takeda Pharmaceutical Company Limited ("Takeda") has announced its intention to launch a voluntary conditional takeover bid on TiGenix.


Takeda intends to acquire 100% of the securities with voting rights or giving access to voting rights of TiGenix not already owned by Takeda or affiliates at a price of EUR 1.78 per share in cash and an equivalent price in cash per American Depositary Share, warrant and convertible bond.

 

Read more at TiGenix website.

Please reload

ARCHIVE
Please reload

SEARCH BY TAGS
Please reload

FOLLOW US